Browse > Article
http://dx.doi.org/10.4110/in.2014.14.3.156

Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer  

Baharlou, Rasoul (Department of Immunology and Microbiology, School of Medicine, Jahrom University of Medical Sciences)
Vasmehjani, Abbas Ahmadi (Department of Immunology and Microbiology, School of Medicine, Jahrom University of Medical Sciences)
Dehghani, Ali (Department of Nursing, School of Nursing, Jahrom University of Medical Sciences)
Ghobadifar, Mohamed Amin (Department of Student Research Committee, School of Medicine, Jahrom University of Medical Sciences)
Khoubyari, Mahshid (Department of Student Research Committee, School of Medicine, Jahrom University of Medical Sciences)
Publication Information
IMMUNE NETWORK / v.14, no.3, 2014 , pp. 156-163 More about this Journal
Abstract
Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-${\beta}$) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-${\beta}$ were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p<0.0001) and TGF-${\beta}$ (p<0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.
Keywords
Bladder cancer; Interleukin-6; Interleukin-17; Transforming growth factor beta;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, and G. Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537.   DOI
2 Zhu, X., L. A. Mulcahy, R. A. Mohammed, A. H. Lee, H. A. Franks, L. Kilpatrick, A. Yilmazer, E. C. Paish, I. O. Ellis, P. M. Patel, and A. M. Jackson. 2008. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10: R95.   DOI
3 Kato, T., H. Furumoto, T. Ogura, Y. Onishi, M. Irahara, S. Yamano, M. Kamada, and T. Aono. 2001. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282: 735-738.   DOI   ScienceOn
4 Chi, L. J., H. T. Lu, G. L. Li, X. M. Wang, Y. Su, W. H. Xu, and B. Z. Shen. 2010. Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin. Exp. Immunol. 161: 480-489.   DOI
5 Lee, J. J., Y. L. Chang, W. L. Lai, J. Y. Ko, M. Y. Kuo, C. P. Chiang, M. Azuma, C. W. Chen, and J. S. Chia. 2011. Increased prevalence of interleukin-17-producing $CD4^+$ tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 33: 1301-1308.   DOI
6 Kwon, K. A., S. H. Kim, S. Y. Oh, S. Lee, J. Y. Han, K. H. Kim, R. Y. Goh, H. J. Choi, K. J. Park, M. S. Roh, H. J. Kim, H. C. Kwon, and J. H. Lee. 2010. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10: 203.   DOI
7 Ravishankaran, P. and R. Karunanithi. 2011. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol. 9: 18.   DOI   ScienceOn
8 Jeon, S. H., B. C. Chae, H. A. Kim, G. Y. Seo, D. W. Seo, G. T. Chun, N. S. Kim, S. W. Yie, W. H. Byeon, S. H. Eom, K. S. Ha, Y. M. Kim, and P. H. Kim. 2007. Mechanisms underlying TGF-${\beta}1$-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J. Leukoc. Biol. 81: 557-566.   DOI   ScienceOn
9 Wang, L., T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206: 1457-1464.   DOI   ScienceOn
10 Radosavljevic, G., B. Ljujic, I. Jovanovic, Z. Srzentic, S. Pavlovic, N. Zdravkovic, M. Milovanovic, D. Bankovic, M. Knezevic, L. J. Acimovic, and N. Arsenijevic. 2010. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 57: 135-144.   DOI
11 Jovanovic, D. V., J. A. Di Battista, J. Martel-Pelletier, F. C. Jolicoeur, Y. He, M. Zhang, F. Mineau, and J. P. Pelletier. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160: 3513-3521.
12 Nam, J. S., M. Terabe, M. J. Kang, H. Chae, N. Voong, Y. A. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68: 3915-3923.   DOI   ScienceOn
13 Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C. S. Hinrichs, K. W. Kerstann, L. Feigenbaum, C. C. Chan, and N. P. Restifo. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.   DOI
14 Ankathatti Munegowda M, Deng Y, Mulligan SJ, and Xiang J. 2011. Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol. Immunother. 60: 1473-1484.   DOI
15 Kolahdoozan S, Sadjadi A, Radmard AR, and Khademi H. 2010. Five common cancers in Iran. Arch. Iran. Med. 13: 143-146.
16 Passos, S. T., J. S. Silver, A. C. O'Hara, D. Sehy, J. S. Stumhofer, and C. A. Hunter. 2010. IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 184: 1776-1783.   DOI
17 Mucida, D. and H. Cheroutre. 2007. TGFbeta and retinoic acid intersect in immune-regulation. Cell Adh. Migr. 1: 142-144.   DOI
18 Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.   DOI   ScienceOn
19 Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, D. Blanchard, C. Gaillard, B. Das Mahapatra, E. Rouvier, P. Golstein, J. Banchereau, and S. Lebecque. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183: 2593-2603.   DOI   ScienceOn
20 Murugaiyan, G. and B. Saha. 2009. Protumor vs antitumor functions of IL-17. J. Immunol. 183: 4169-4175.   DOI
21 Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Fili, S. Ferri, F. Frosali, F. Giudici, P. Romagnani, P. Parronchi, F. Tonelli, E. Maggi, and S. Romagnani. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861.   DOI   ScienceOn
22 Honorati, M. C., S. Neri, L. Cattini, and A. Facchini. 2006. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts1. Osteoarthritis Cartilage 14: 345-352.   DOI
23 Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 2005. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 175: 5-14.
24 Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.   DOI   ScienceOn
25 Peck, A. and E. D. Mellins. 2009. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin. Immunol. 132: 295-304.   DOI   ScienceOn
26 Sfanos, K. S., T. C. Bruno, C. H. Maris, L. Xu, C. J. Thoburn, A. M. DeMarzo, A. K. Meeker, W. B. Isaacs, and C. G. Drake. 2008. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14: 3254-3261.   DOI
27 Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178: 6730-6733.   DOI
28 Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8: 337-348.   DOI   ScienceOn
29 Chen, M. F., P. Y. Lin, C. F. Wu, W. C. Chen, and C. T. Wu. 2013. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 8: e61901.   DOI
30 Yang, L., Y. Qi, J. Hu, L. Tang, S. Zhao, and B. Shan. 2012. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem. Biophys. 62: 153-159.   DOI   ScienceOn
31 Weaver, C. T. and R. D. Hatton. 2009. Interplay between the TH17 and TReg cell lineages: a (co-) evolutionary perspective. Nat. Rev. Immunol. 9: 883-889.   DOI   ScienceOn
32 Khatami, M. 2009. Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases. Cell Biochem. Biophys. 55: 55-79.   DOI   ScienceOn
33 Erdman, S. E. and T. Poutahidis. 2010. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol. 38: 76-87.   DOI   ScienceOn
34 Connolly, E. C., J. Freimuth, and R. J. Akhurst. 2012. Complexities of TGF-beta Targeted Cancer Therapy. Int. J. Biol. Sci. 8: 964-978.   DOI
35 Zhang, B., G. Rong, H. Wei, M. Zhang, J. Bi, L. Ma, X. Xue, G. Wei, X. Liu, G. and Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537.   DOI
36 Zhang, J. P., J. Yan, J. Xu, X. H. Pang, M. S. Chen, L. Li, C. Wu, S. P. Li, and L. Zheng. 2009. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50: 980-989.   DOI
37 Shime, H., M. Yabu, T. Akazawa, K. Kodama, M. Matsumoto, T. Seya, and N. Inoue. 2008. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 180: 7175-7183.   DOI